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eliana@ufp.edu.pAbstract Didanosine is an effective antiviral drug in untreated and antiretroviral therapy-experienced patients
with Human Immunodeﬁciency Virus (HIV). An automated system using on-line solid extraction and High
Performance Liquid Chromatography (HPLC) with ultraviolet (UV) detection was developed and validated
for pharmacokinetic analysis of didanosine in dog plasma. Modiﬁcations were introduced on a previous
methodology for simultaneous analysis of antiretroviral drugs in human plasma. Extraction was carried out on
C18 cartridges, with high extraction yield as stationary phase, whereas mobile phase consisted of a mixture of
0.02 M potassium phosphate buffer, acetonitrile (KH2PO4: acetonitrile: 96:4, v/v) and 0.5% (w/v) of heptane
sulphonic acid. The pH was adjusted to 6.5 with triethylamine. All samples and standard solutions were
chromatographed at 28 1C. For an isocratic run, the ﬂux was 1.0 mL/min, detection was at 250 nm and injected
volume was 20 mL. The method was selective and linear for concentrations between 50 and 5000 ng/mL. Drug
stability data ranged from 96% to 98%, and limit of quantiﬁcation was 25 ng/mL. Extraction yield was up to 95%.
Drug stability in dog plasma was kept frozen at 20 1C for one month after three freeze–thaw cycles, and for 24 h
after processing in the auto sampler. Assay was successfully applied to measure didanosine concentrations in
plasma dogs.
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P. Severino et al.301. Introduction
Didanosine is an important antiretroviral for Acquired
Immune Deﬁciency Syndrome (AIDS) for producing beneﬁ-
cial effects on virological and immunological markers of
Human Immunodeﬁciency Virus (HIV) disease, improving
clinical outcome in adults or children with HIV infection
[1,2]. It is a synthetic, intracellularly phosphorylated nucleo-
side analogous to the active metabolite, which inhibits the
activity of HIV reverse transcriptase by competing with the
natural substrate [3,4]. However, it exhibits a low oral
bioavailability because of poor permeability across the
intestinal epithelium [5,6]. Antiretroviral agents may be
potential candidates for therapeutic drug monitoring to con-
trol efﬁcacy and toxicity [7,8]. Our group has previously
developed granules containing chitosan microspheres [9]
encapsulating didanosine, which increased half life (t1/2),
promoting the sustained delivery for 36 h, compared to the
free buffer tablets and gastro-resistant granules, Videxs EC,
following a pharmacokinetic proﬁle. Since solid dosage forms
cannot be administered in rats, pharmacokinetic analysis of
didanosine was tested in male adult dogs. To quantify
didanosine in dog plasma, a modiﬁed solid phase extraction
(SPE) method for sample clean-up was carried out, followed
by an on-line reversed phase high performance liquid chro-
matography (HPLC) with ultraviolet (UV) detection. The
methodologies reported in the literature for analysis of
didanosine in biological samples use SPE together with HPLC
methods and UV detection for simultaneous analysis of
groups of antiretrovirals in human plasma, such as abacavir,
amprenavir, didanosine, efavirenz, nevirapine, and stavudine
[10]. Plasma analysis using chromatographic methods always
involves a sample preparation procedure using, e.g. liquid–
liquid [11], solid–liquid extraction [12], or protein precipitation
[13].
The application of SPE for analyses of biological matrices
allows either higher recoveries or the elimination of some possible
interference from co-administered drugs. It can be labor-intensive
and prone to errors. A direct injection technique eliminates
multiple sample pre-treatment steps and can increase the through-
put of many bioanalytical methods. Automated sample processing
reduces potentially dangerous sample handling [14]. In particular,
SPE should be used for the analysis of didanosine, because this
drug is poorly soluble in organic solvents.
Campbell et al. [15] developed and validated a high-
performance liquid chromatographic assay for simultaneous
determination of 20-ﬂuoro-20 30-dideoxyadenosine (FddA) and
its metabolite, 20-ﬂuoro-20, 30-dideoxyinosine (Fddl), in dog
plasma and urine. SPE was applied to extract FddA, Fddl,
and the internal standard (30,50-anhydrothymidine) from the
biological samples. The collected samples were chromato-
graphed using a C8 column coupled with a mobile phase
consisting of monobasic phosphate, dibasic phosphate, ethy-
lene glycol monomethyl ether, and water.
Some reports describe simultaneous determination of HIV
drugs by HPLC with tandem mass spectrometry in plasma.
This methodology can be used for pharmacological research
and clinical purposes in rats [16,17] and humans [18–21]. In
another study, Yan et al. [5] developed a rapid and efﬁcient
HPLC–tandem mass spectrometry coupled with SPE for
determining didanosine concentrations in maternal rat
plasma, amniotic ﬂuid, placental and fetal tissue samples.The method was developed and validated, and the results
showed limits of detection of 1 ng/mL. Recoveries were 70%
or greater for didanosine and valdidanosine compounds in
the different matrices. Within and between run precision
(%RSD) and accuracy (%error) were less than 15% for all
matrices.
In this paper, we describe a modiﬁed method, which was
validated for the analysis of didanosine in dog plasma, using
the SPE C18 cartridges (Bond Elut
s), the HPLC stationary
phase C18 column. The mobile phase consisted of a mixture
of potassium phosphate buffer, acetonitrile, and heptane
sulphonic acid. The method was validated according to
published FDA guidelines [22]. In general, analyses described
in the literature, using HPLC methods and UV detection
(240–260 nm), use mobile phase gradient elution; detection
for drug concentrations ranges between 0.005 and 10 mg/mL,
and the injected volume is 650 mL [10]. The advantages of our
method include the smallest volume of sample (20 mL), which
is needed for pharmacokinetic studies in animals, the adjust-
ment of the mobile phase proportion for didanosine only,
isocratic elution, and lower quantiﬁcation levels (from 20 to
4500 ng/mL).2. Experimental
2.1. Materials and reagents
Didanosine was provided by Labogen Quı´mica Fina e Biotec-
nologia S.A. (Indaiatuba, Brazil); Didanosine buffered tablets
were received as a gift from the Brazilian Government Health
Agency. Acetonitrile and methanol (HPLC grade) and triethy-
lamine were purchased from Mtedias (S~ao Paulo, Brazil).
Acyclovir (internal standard) was obtained from Henrifarma
(S~ao Paulo, Brazil). Heptane sulphonic acid (ion-exchange) was
obtained from J.T. Bakers (Campinas, Brazil). Distilled water
was puriﬁed by a Milli-Q system (Millipores).2.2. Preparation of sample solutions
Didanosine solution was prepared in 0.01 M potassium phos-
phate buffer, pH¼7, with a ﬁnal concentration of 0.2 mg/mL.
The same procedure was followed using acyclovir as internal
standard. These dilutions were used to sample plasma for the
preparation of calibration curves. The standard stock solutions
were prepared in triplicate for the calibration curve, the ﬁnal
concentrations of didanosine in dog plasma were 500, 1000,
2500, 5000, 10,000, 20,000, and 50,000 ng/mL with 0.2 mg/mL of
acyclovir. Quality control (QC) samples were prepared at
concentrations of 75, 1500, and 3500 ng/mL, and were used for
validating the analytical method. The internal standard was
added in all samples in a concentration of 0.2 mg/mL. Prelimin-
ary tests were carried out using a concentration range until the
minimum and maximum values were obtained.2.3. On-line SPE system and HPLC conditions
From the analytical methodology described by Notari et al. [10],
the conditions were adjusted for the simultaneous determination
of didanosine and acyclovir as an internal standard in dog
In vivo absorption of didanosine tablets 31plasma. The method used in the on-line SPE was Prospekt 2TM
(Spark Holland, Emmen, The Netherlands) on-line SPE system,
consisting of the following modules: automated cartridge
exchange (ACE) module for disposable cartridge exchange,
high-pressure dispenser (HPD) module for handling of solvents
and an auto sampler Triathlon. Prospekt 2TM was controlled
using SparkLinkTM. The SPE cartridges used consisted of
BondElut C18, 10 mm 2 mm i.d., 40–90 mm particles. HPLC
apparatus consisted of a Shimadzu system equipped with LC-
10AD VP pump with a low-pressure gradient ﬂow control valve
FCV-10AL VP, SCL-10A VP system controller, SIL-10AD VP
auto-injector. Shimadzu CLASS-VP software (Version 6.12) was
used for data acquisition and mathematical calculations. The
chromatography was done by HPLC column C18 15 cm 4 mm,
V04-745, preceded by a guard column ACEs 5C18, V03-417,
Analiticas. All samples and standard solutions were chromato-
graphed at 28 1C (standardized lab temperature), using a
mixture of potassium phosphate buffer (0.02 M) and acetonitrile
(96:4, v/v), added with 0.5% (w/v) of heptane sulphonic acid as
mobile phase. The pH was adjusted at 6.5 with triethylamine.
The ﬂux was 1.0 mL/min; injection samples were 20 mL, and UV
detectors were set at 250 nm.
2.4. Sample preparation by SPE
To prepare the calibration curves, 10 mL of didanosine and
10 mL of internal standard, acyclovir, were added to each
90 mL of dog plasma at different concentrations to obtain the
ﬁnal desired plasma concentrations, and the mixture was
vortexed. Quality controls and plasma samples for the phar-
macokinetic study followed the same procedures. The injec-
tion and the extraction were completely automated using the
Prospekt2TM system; the cartridge was solvated with 1000 mL
of methanol at 3000 ml/min and equilibrated with 1000 mL of
water at the same ﬂow rate. After the plasma sample was
injected into the cartridge, it was eluted with 500 mL of water
at 1000 mL/min to retain didanosine and acyclovir, and to
eliminate plasma proteins. The cartridge was then washed with
1000 mL of water and 1000 mL of methanol/water (50:50) in
ﬂux 3000 mL/min. The cartridge was automatically changed
for a new one, and a new cycle started.
2.5. Calibration curve and validation
The analytical performance of the method was obtained by
evaluation of the following parameters: calibration curve
linearity, QC intra-day and inter-day precision and accuracy,
lower limit of quantiﬁcation (LLOQ), speciﬁcity and stability
data [22]. To determine the linearity of the method, six
calibration curves with seven calibration points ranging from
50 to 5000 ng/mL were prepared in duplicate and analyzed on
two consecutive days. Linear regression analysis of the data
from calibration curves gave slope, intercept and correlation
coefﬁcients, which were used to determine the concentration of
each analyte in the QC control samples. The lowest concen-
tration level giving a chromatographic response with accep-
table coefﬁcient of variation was deﬁned as the LLOQ. To
determine precision and accuracy, QC samples of didanosine
were prepared in triplicate at four concentration levels (25, 75,
2500 and 4500 ng/mL) and analyzed using the procedure
outlined above.2.6. Preliminary stability studies
The stability of didanosine and the internal standard in
plasma was studied in three experimental conditions: during
three freeze–thaw cycles and after storage at the autosampler
carrousel at room temperature, these samples were analyzed in
zero time, 12 h and 24 h; and long-term stability in serum was
assessed after 1 month storage at 20 1C. Stability was
evaluated by comparing the obtained concentrations before
and after storage. The analyses were carried out in triplicate.
2.7. Pharmacokinetic study
The protocol used for didanosine pharmacokinetic evaluation
was previously approved by the Ethics in Research Committee
of Universidade Federal do Rio Grande do Sul-UFRGS
(#2007760). Experiments with dogs were carried out in the
Center of Research in Animal Health of the School of
Agrarian Science and Veterinary of UNESP (CPPAR/
Unesp-Jaboticabal-SP). A pilot study was carried out to
demonstrate the applicability of the developed method. Adult
male dogs (10 kg) were given vermifuges a week before the
experiment, and were kept separately. The dogs fasted for 12 h
before administration and received water and food 2 h after
administering the formulation. Didanosine was available as
didanosine tablets distributed by Brazilian Government’s
Health Agency administered orally as a single dose of
500 mg with 10 mL of water (n¼9). Blood samples (2 mL)
were collected from the cephalic vase with heparinized
VACUETTEs before drug administration (time 0) and at
0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 18, 24, and 36 h after
administration. Blood cells were removed by centrifugation
for 10 min at 9000 rpm and the separated plasma was stored at
20 1C until assay. Pharmacokinetic parameters were deter-
mined by non-compartmental approach. The elimination rate
constant (kel) was calculated by log-linear regression of the
didanosine concentration during the elimination phase and the
half-life (t1/2) was calculated as 0.693/kel. Didanosine peak
plasma concentration (Cmax) and time of peak (tmax) were
obtained by visual inspection of the concentration–time
proﬁles. The area under the plasma concentration versus time
curve (AUC0–t) from time zero to the time of last concentra-
tion measured (Clast) was calculated by the log-linear trape-
zoidal rule. The AUC zero to inﬁnity (AUC0–N) was obtained
by the addition of AUC0–t and the extrapolated area was
determined by Clast/kel.3. Results and discussion
The modiﬁed HPLC method provided a simple and fast
procedure for the quantiﬁcation of didanosine in dog plasma
samples. Preliminary studies with different mobile phase
combinations of phosphate buffer and acetonitrile were
considered. Different pH values of the mixture were also
evaluated. Chromatographic conditions were based on iso-
cratic separation on a reverse phase column, preceded by a
guard-column.
The LLOQ was 25 ng/mL, which was the lowest concentra-
tion of analyte in our modiﬁed method. This concentration
presented an accuracy that does not deviate more than 20% of
the actual value, and its precision does not exceed 20% of the
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FDA Guidelines.
Plasma samples were collected with different concentration
levels of didanosine and were analyzed using the optimum
SPE conditions. The linearity of the standard curve was
checked in 6 different runs after calculating individual slopes
and intercepts of each individual curve according to Table 1.
The correlation coefﬁcient was Z0.9994 for all calibration
curves in plasma.
Intra-assay, inter-assay precision and accuracy were per-
formed. The results are reported in Table 2. Acceptable accuracy
was achieved for all concentrations investigated and these values
are considered adequate for biological samples.
When analyzing drugs from biological ﬂuids using SPE,
adequate selection of the convenient extraction conditions
(sample pH, composition of the washing and elution solvents,
and the nature of the sorbent material) provides the cleanest
samples for the chromatographic analysis being an important
factor for the selectivity of the entire analytical method. The
correct selection of SPE washing and elution solvents provided
very clean samples and an adequate selectivity for the
analytical method developed. The optimum conditions were
obtained using BondElut C18 cartridges. As the chromato-
grams in Fig. 1 show, the retention time of acyclovir (internalTable 1 Linearity of the standard curve in six runs.
Day Run Intercepts Slope Correlation
coefﬁcient
1 1 0.0162 0.0005 0.9972
2 0.0302 0.0005 0.9981
3 0.0058 0.0006 0.9964
2 1 0.0119 0.0005 0.9994
2 0.0659 0.0005 0.9994
3 0.0670 0.0006 0.9987
Average 0.0328 0.0005 0.9994
SD 0.0272 0.00005
RSD 9.43
SD: Standard deviation; RSD: Relative standard deviation.
Table 2 Intra- and inter-day assay precision of the HPLC assay
Nominal concentration
(ng/mL)
Measured concentration (ng/ML)a
Day 1 Day 2
Intra-day
25 26.074.5 28.072.6
75 83.072.8 82.077.0
2500 2526.0779.0 2637.07294.
4500 4485.07409.0 4467.0748.0
Inter-day
25 27.071.4
75 82.570.7
2500 2581.0778.4
4500 4476.0712.7
aMean7SD.
bCV: coefﬁcient of variation.standard) and didanosine was approximately 2.2 and 4.5 min,
respectively.
The concentrations of didanosine and acyclovir in plasma
samples during three freeze–thaw cycles and in the auto
sampler carrousel for 24 h at room temperature did not reduce
signiﬁcantly in relation to time zero (Table 3). These results
reveal the stability of both drugs in processed plasma samples
during the time of analysis. The samples were stable in plasma
at 20 1C for at least 1 month, with stability data up to 95%
in relation to zero time. Thus, the data show that didanosine
concentrations remained unchanged under the conditions
employed in the study. From these results didanosine stability
in dog plasma was conﬁrmed (Table 4).(n¼6).
Accuracy (%) CVb (%)
Day 1 Day 2 Day 1 Day 2
104 112 17.6 9.4
110 109 3.4 8.5
0 101 105 3.1 11.1
99 99 9.1 1.0
108.0 5.2
110.0 0.8
103.5 3.0
99.4 0.2
0
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0
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40
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0 654321
0 654321
Figure 1 HPLC chromatograms of blank dog plasma (A) and of
dog plasma after didanosine and acyclovir intake (B).
Table 3 Plasma samples in auto sampler carrousel for
24 h at room temperature.
Concentration
(ng/mL)
Concentration found (ng/mL) Stability
(%)
Zero 12 h 24 h
25 25.070.1 24.070.3 24.070.3 96
4500 4459.070.5 4450.070.4 4400.070.6 97
Table 4 Plasma samples during three freeze–thaw cycles.
Concentration
(ng/mL)
Concentration found (ng/mL) Stability
(%)
Cycle 1 Cycle 2 Cycle 3
25 24.070.4 24.070.2 24.070.4 96
4500 4450.0710.0 4449.075.0 4439.0710.0 98
0 4 6 8 10 122
0
2
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8
10
C
on
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nt
ra
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n 
(µ
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L)
Time (h)
Figure 2 Mean plasma concentration–time proﬁle after a single
oral dose of 50 mg/kg of didanosine in dog (n¼9).
In vivo absorption of didanosine tablets 33The developed SPE–HPLCmethod was employed to determine
the pharmacokinetic proﬁle of didanosine after a single oral dose
of 500 mg was given to each dog. Didanosine average concentra-
tion versus time proﬁle is shown in Fig. 2. The error bars were
below 1%. The peak plasma concentration was 793571.05 ng/mL
and it took place at 1 h. The half-life of the elimination phase was
5.472.4 h. The AUC0–N was 2075 mg h/mL and extrapolated
AUC (AUCt–N) was 271 mg h/mL, around 10% of the total
AUC, demonstrating that the sensitivity of the method developed
is sufﬁcient to allow quantifying the drug in dog plasma for a
period of time long enough to adequately characterize its
elimination phase.4. Conclusions
A bioanalytical modiﬁed method for didanosine quantiﬁcation
in dog plasma has been developed and validated, and didano-
sine showed to be stable in this process. The method reported
the analysis of didanosine in plasma by combining a rapid and
efﬁcient on-line SPE with a speciﬁc and sensitive quantiﬁcation
by HPLC with UV detection. The validation parameters are in
accordance with the FDA Guidelines.Acknowledgments
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